Navigation Links
HeartWare International, Inc. Announces Concurrent Public Offerings of Convertible Senior Notes and Common Stock
Date:12/9/2010

le would be unlawful prior to registration or qualification under the securities laws of such state.  The issuer has filed a registration statement (including a prospectus) with the SEC for the offerings to which this communication relates.  Each offering of securities will be made only by means of a prospectus and the related prospectus supplement.  Before you invest, you should read the prospectus and the related prospectus supplement and any other document HeartWare has filed with the SEC for more complete information about HeartWare and the respective offering.  You may get these documents for free by visiting EDGAR on the SEC Website at www.sec.gov.  Alternatively, copies of the prospectus and the related prospectus supplement can be obtained by contacting J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by calling 1-866-803-9204.

About HeartWare International HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat patients suffering from advanced heart failure.  

Forward-Looking Statements This announcement contains forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.  All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to regulatory submissions and approvals such as FDA approval of our expected premarket approval application for our HeartWare® Ventricular Assist System for a bridge-to-transplant indication; our expectations with respect to our clinical trials, including enrollment in or completion of our clinical trials; our expectations with respect to the inte
'/>"/>

SOURCE HeartWare International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. HeartWare to Present at the Canaccord Genuity Cardio/Diabetes & Obesity Conference
2. HeartWare Achieves Primary Endpoint with 92% Success in Pivotal Bridge-to-Transplant Clinical Trial, ADVANCE
3. HeartWare to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
4. HeartWare Bridge-to-Transplant Data Featured as Late Breaking Clinical Trial at American Heart Association Scientific Sessions 2010
5. HeartWare International Reports Third Quarter 2010 Revenues of $13.8 Million; Compared to $7.5 Million in Third Quarter of 2009
6. HeartWare to Report Financial Results for Third Quarter of 2010
7. HeartWare to Present at Lazard Capital Markets Circulatory Assist Device Day
8. HeartWare to Present at the UBS 2010 Global Life Sciences Conference
9. HeartWare to Present at 21st Annual Piper Jaffray Health Care Conference in New York City
10. HeartWare International Reports Third Quarter Revenues of $7.5 Million
11. U.S. FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U.S. Bridge-to-Transplant Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers ... technologies must be able to protect their ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) ... of the Medical Device Industry, it steadfastly ... sectors of cases involving IP infringement. This ...
(Date:1/15/2014)... R.I. , Jan. 15, 2014 MultiCell ... has filed a U.S. provisional patent application concerning composition ... formulations to achieve targeted tumor cell death.  ... very small noncoding double stranded RNA molecules (VSRNAs) which ... cells. VSRNAs are of molecular size less than 10 ...
(Date:1/15/2014)... 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ... growth of these markets. The European ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... Inc. (Nasdaq: ALXA ) today announced that company ... will present during the MDB Bright Lights Conference 2011.  The ... 10:00 a.m. Eastern Time.  The presentation will be webcast live ... via the Web, please go to the Investor Relations tab ...
... DIEGO, May 6, 2011 Arena Pharmaceuticals, Inc. (NASDAQ: ... to present at the Bank of America Merrill Lynch 2011 Health ... Time (1:00 p.m. Eastern Time) at the Encore at the Wynn ... Ph.D., Arena,s Vice President, Lorcaserin Development, is scheduled to provide a ...
Cached Medicine Technology:Alexza to Present at the MDB Bright Lights Conference 2011 2Alexza to Present at the MDB Bright Lights Conference 2011 3Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference 2Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference 3
(Date:4/14/2014)... Therapeutics, Inc., announced today a publication demonstrating that ... human red blood cells exposed to plasma samples ... anemia (AIHA). The article entitled "TNT003, an inhibitor ... induced by cold agglutinin disease patient autoantibodies" was ... earlier this month. TNT003 is the murine analog ...
(Date:4/14/2014)... around the world, many people live and work in ... block sunlight. And as the global population continues to ... will only spread. , To alleviate the problem, ... redirects sunlight onto narrow streets and alleyways. The panel ... at an angle, where it spreads sunlight onto the ...
(Date:4/14/2014)... professor of chemical engineering at Virginia Tech , ... analyze living cells. The long-term goal is to gain ... In his lab , Lu and his students ... events inside cells. These devices promote high sensitivity and ... cells. , Based on their record of achievements, the ...
(Date:4/14/2014)... April 2014, Perth, Australia. Drug discovery company Proteomics ... development of a companion diagnostic (CDx) test with ... , The research team authenticated the panel of ... control samples. Seven biomarkers were validated at high ... , The mass spectrometry data was then cross-validated ...
(Date:4/14/2014)... guidelines for high-risk bladder cancer, chemotherapy before or ... clinical practice. The findings are published early online ... the American Cancer Society. , Clinical trials have ... muscle-invasive bladder cancer who are given chemotherapy before ... after surgery also improves survival. To investigate the ...
Breaking Medicine News(10 mins):Health News:Ex vivo efficacy of C1s antibody as Complement inhibitor in cold agglutinin disease 2Health News:Let the sun shine in: Redirecting sunlight to urban alleyways 2Health News:Efficient analysis of small quantity of cells improves chances to understand disease 2
... /PRNewswire/ -- Aesthetic Medical Educators ... medical professionals on Aesthetic Procedures over the past ... training include physicians, nurses, physician assistants and dentists, ... in his/her practice.These medical professionals have been trained ...
... Convene in Washington D.C. ... Pass Legislation that Will Protect the Public WASHINGTON, April ... of foodborne illness, including surviving family members of those ... Capitol to share their stories, meet with legislators and ...
... -- With the 2009 NBA playoff season ... public affairs television program that tells the compelling and ... and diabetes patient Dominique Wilkins. Sharing Miracles ... stations. A nine-time NBA all-star who spent the majority ...
... Controls Limit Vaccine SuppliesDALLAS, April 29 Fears of ... new vaccines, as well as meeting public demand for ... National Center for Policy Analysis. "We are facing ... six vaccines for common childhood illnesses," said NCPA Senior ...
... Executive Chairman & CEO Douglas MacLellan offers expert insight ... April 29 AMDL Inc. ... major operations in China, announced today its Executive Chairman ... featured in The Wall Street Transcript - ...
... appear to be safe, but more research needed ... shows promise in treating diabetic polyneuropathy, a disorder that ... years, a new study finds. , Researchers in Boston ... (VEGF) gene may help patients with diabetic polyneuropathy. The ...
Cached Medicine News:Health News:Aesthetic Medical Educators Training Successfully Trains Over 2,000 Medical Professionals on Aesthetic Procedures 2Health News:Foodborne Illness Victims Mark President Obama's First 100 Days By Calling For Permanent Fix To Food Safety System 2Health News:Foodborne Illness Victims Mark President Obama's First 100 Days By Calling For Permanent Fix To Food Safety System 3Health News:'Sharing Miracles' Television Program to Feature NBA Hall-of-Famer, Scoring Champ Dominique Wilkins 2Health News:'Sharing Miracles' Television Program to Feature NBA Hall-of-Famer, Scoring Champ Dominique Wilkins 3Health News:'Sharing Miracles' Television Program to Feature NBA Hall-of-Famer, Scoring Champ Dominique Wilkins 4Health News:'Sharing Miracles' Television Program to Feature NBA Hall-of-Famer, Scoring Champ Dominique Wilkins 5Health News:'Sharing Miracles' Television Program to Feature NBA Hall-of-Famer, Scoring Champ Dominique Wilkins 6Health News:'Sharing Miracles' Television Program to Feature NBA Hall-of-Famer, Scoring Champ Dominique Wilkins 7Health News:'Sharing Miracles' Television Program to Feature NBA Hall-of-Famer, Scoring Champ Dominique Wilkins 8Health News:Swine Flu Outbreak Illustrates Problems in Vaccine Development 2Health News:Chinese Pharma Market Continues to Grow at a 5-7% Rate in 2009; AMDL Remains on Track to Meet FY09 Financial Targets 2Health News:Chinese Pharma Market Continues to Grow at a 5-7% Rate in 2009; AMDL Remains on Track to Meet FY09 Financial Targets 3Health News:Gene Therapy Improves Diabetic Neuropathy in Study 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: